Adjusting and censoring electronic monitoring device data: Implications for study outcomes

Journal of Acquired Immune Deficiency Syndromes

Volumn 43, Issue SUPPL. 1, 2006, Pages

  Fennie, Kristopher P ^a,c   Bova, Carol A ^b   Williams, Ann B ^a  

^a YALE UNIVERSITY   (United States)

^b UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^c YALE UNIVERSITY SCHOOL OF NURSING   (United States)

Author keywords

Censoring; Data adjustment; Electronic monitoring device; Measurement; Medication adherence

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; LAMIVUDINE;

ARTICLE; CLINICAL RESEARCH; DECISION MAKING; DEVICE; ELECTRONIC MONITORING DEVICE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFORMATION PROCESSING; PATIENT COMPLIANCE; PILL; PRIORITY JOURNAL; SELF REPORT; TECHNIQUE; TREATMENT OUTCOME;

ANTI-HIV AGENTS; DATA COLLECTION; DRUG MONITORING; DRUG PACKAGING; HIV INFECTIONS; HUMANS; MEDICAL RECORDS; PATIENT COMPLIANCE; RESEARCH;

EID: 33845359280     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.qai.0000248336.97814.2f     Document Type: Article

References (21)

1. Farmer KC. Methods for measuring and monitoring medication regimen adherence in clinical trials and clinical practice. Clin Ther. 1999;21:1074-1090.
2. Dunbar-Jacob J, Erlen JA, Schlenk EA, et al. Adherence in chronic disease. Annu Rev Nurs Res. 2000;18:48-90.
3. Sereika SM, Dubar-Jacob J. Analysis of electronic event monitored adherence. In: Burke LE, Ockene IS, eds. Compliance in Healthcare and Research. Armonk, NY: Futura Publishing Company; 2001;139-162.
4. Girard P, Blaschke TF, Kastrissios H, et al. A Markov mixed effect regression model for drug compliance. Stat Med. 1998;17:2313-2333.
5. Knafl GJ, Fennie KP, Bova C, et al. Electronic monitoring device event modelling on an individual-subject basis using adaptive Poisson regression. Stat Med. 2004;23:783-801.
6. Dunsiger S, Hogan J, Gifford A. Classification of longitudinal drug adherence patterns from MEMS cap time series data. Presented at: National Institute of Mental Health/International Association of Physicians in AIDS Care International Conference on HIV Treatment Adherence; 2006; Jersey City.
7. Liu H, Miller LG, Hays RD, et al. Predictors of virologic responses to HAART: dose timing, overall adherence, and genotypic sensitivity. Presented at: National Institute of Mental Health/International Association of Physicians in AIDS Care International Conference on HIV Treatment Adherence; 2006; Jersey City.
8. Vrijens B, Goetghebeur E, de Klerk E, et al. Modelling the association between adherence and viral load in HIV-infected patients. Stat Med. 2005;24:2719-2731.
9. Bova CA, Fennie KP, Knafl GJ, et al. Use of electronic monitoring devices to measure antiretroviral adherence. Practical considerations. AIDS Behav. 2005;9:103-110.
10. Lehman HP, Benson JO, Beninger PR, et al. A five-year evaluation of reports of overdose with indinavir sulfate. Pharmacoepidemiol Drug Saf. 2003;12:449-457.
11. Moss AR, Hahn JA, Perry S, et al. Adherence to highly active antiretroviral therapy in the homeless population in San Francisco: a prospective study. Clin Infect Dis. 2004;39:1190-1198.
12. Friedland GH, Williams A. Attaining higher goals in HIV treatment: the central importance of adherence. AIDS. 1999;13(Suppl 1):S61-S72.
13. Bangsberg DR, Weiser S, Guzman D, et al. 95% adherence is not necessary for viral suppression to <400 copies/mL in the majority of individuals on NNRTI regimens. Presented at: 12th Conference on Retroviruses and Opportunistic Infections; 2005; Boston.
14. Wagner GJ. Predictors of antiretroviral adherence as measured by self-report, electronic monitoring, and medication diaries. AIDS Patient Care STDS. 2002;16:599-608.
15. Golin CE, Liu H, Hays RD, et al. A prospective study of predictors of adherence to combination antiretroviral medication. J Gen Intern Med. 2002;17:812-813.
16. Oyugi JH, Byakika-Tusiime J, Charlebois ED, et al. Multiple validated measures of adherence indicate high levels of adherence to generic HIV antiretroviral therapy in a resource-limited setting. J Acquir Immune Defic Syndr. 2004;36:1100-1102.
17. Fletcher CV, Testa MA, Brundage RC. Four measures of antiretroviral medication adherence and virologic response in AIDS Clinical Trials Group Study 359. J Acquir Immune Defic Syndr. 2005;40:301-306.
18. Remien RH, Stirratt MJ, Dolezal C, et al. Couple-focused support to improve HIV medication adherence: a randomized controlled trial. AIDS. 2005;19:807-814.
19. Liu H, Golin CE, Miller LG, et al. A comparison study of multiple measures of adherence to HIV protease inhibitors. Ann Intern Med. 2001;134:968-977.
20. Bova CA. One measurement challenge: getting conceptually clear. Presented at: Enhancing Adherence Conference; 2005; New Haven.
21. Moher D, Schulz KF, Altman DG, et al. The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials. Ann Intern Med. 2001;134:657-662.